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S. Anwar Jagessar1,2*, Nicole Heijmans1, Erwin L A Blezer3, Jan Bauer4, Robert Weissert5 and Bert A. ‘t Hart1,2,6*Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset monkey (Callithrix
jacchus) is a relevant preclinical model for translational research into immunopathogenic mechanisms operating in
multiple sclerosis (MS). Prior studies showed a core pathogenic role of T and B cells specific for myelin oligodendrocyte
glycoprotein (MOG). However, in those studies, the quality of the response against MOG epitopes was strongly biased
by bacterial antigens in the complete Freund’s adjuvant (CFA), in which the immunizing recombinant human (rh) MOG
protein had been formulated. In response to the need of a more refined EAE model, we have tested whether disease
could also be induced with rhMOG in incomplete Freund’s adjuvant (IFA).
Method: Marmosets were immunized with rhMOG emulsified in IFA in the dorsal skin. Monkeys that did not
develop neurological deficit were given booster immunizations at 28-day interval with the same antigen preparation.
In a second experiment, three marmoset twin pairs were sensitized against MOG peptides in IFA to study a possibility
for suppressive activity towards pathogenic T cells directed against the encephalitogenic epitope MOG40-48.
Results: Despite the absence of strong danger signals in the rhMOG/IFA inoculum, all monkeys developed
clinically evident EAE symptoms. Moreover, in all monkeys, demyelinated lesions were present in the white
matter and in two cases also in the cortical grey matter. Immune profiling at height of the disease showed
a dominant T cell response against the overlapping peptides 14–36 and 24–46, but reactivity against the
pathogenically most relevant peptide 34–56 was conspicuously absent. In the second experiment, there was
an indication for a possible suppressive mechanism.
Conclusions: Immunization of marmoset monkeys with rhMOG in IFA elicits clinical EAE in all animals.
Moreover, rhMOG contains pathogenic and regulatory epitopes, but the pathogenic hierarchy of rhMOG
epitopes is strongly influenced by the adjuvant in which the protein is formulated.
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Experimental autoimmune encephalomyelitis (EAE) in the
common marmoset (Callithrix jacchus), a small-bodied
Neotropical primate, is a valid preclinical model of the hu-
man neuroinflammatory disease multiple sclerosis (MS).
The genetic and immunological proximity of the marmo-
set to humans makes the model particularly useful for
translational research into immunopathogenic mecha-
nisms as a basis for new therapies (for review, [1, 2]).
To set up the EAE model, we essentially replicated
well-established mouse models of EAE, the chronic re-
lapsing model in Biozzi ABH mice for example [3].
Randomly selected marmosets were immunized with
human myelin isolated from the brain of a MS patient,
which was formulated with complete Freund’s adjuvant
(CFA) [4]. We showed that, just like in the mouse
model, myelin oligodendrocyte glycoprotein (MOG) is
an essential myelin component for the induction of
progressive disease [5, 6]. In subsequent studies, we de-
termined the critical T cell epitopes in an EAE model
induced with recombinant human MOG (rhMOG) for-
mulated with CFA. We noticed that the initiation and
progression of the disease are mediated by different
pathogenic mechanisms (reviewed in [1]). Briefly, EAE
initiation involves the activation of MHC class II/Caja-
DRB*W1201-restricted T helper (Th) 1 cells specific for
the epitope MOG24-36 [7]. Consistent with this clas-
sical mouse EAE-like paradigm, we observed a strong
clinical effect of prophylactic treatment with ustekinu-
mab, a humanized monoclonal antibody (mAb) against
the joint p40 subunit of interleukins (IL)-12 and -23
[8]. We discovered that full clinical development of
EAE involves transition to a previously unknown
pathogenic mechanism, mediated by MHC class I/Caja-
E-restricted effector memory cytotoxic T cells (CTL)
specific for the epitope MOG40-48 [9]. Later, Zaguia
et al. reported that similar pathogenic cells could be
found in MS lesions [10].
The observation that full clinical EAE development
could be induced by immunizing marmosets with a
synthetic peptide representing residues 34 to 56 of
rhMOG (peptide MOG34-56) formulated with incom-
plete Freund’s adjuvant (IFA), i.e. a formulation lack-
ing the normally requisite danger signals, illustrates
the remarkably high reactivity of the CTL [11]. Of
note, immunization of immunologically naïve, SPF-
bred, Biozzi ABH or C57BL/6 mice with the same
formulation had no detectable effect [11]. We ob-
served that the CTL in marmosets may be recruited
from a repertoire of anti-viral T cells [12] and that B
cells infected with the EBV-related marmoset γ-herpes
virus CalHV3 are involved in the activation of the
CTL [13, 14]. Finally, we observed that the CTL in-
duce demyelination without the support of anti-MOGantibodies, probably by killing oligodendrocytes [15],
as was also observed in MS lesions [10].
The marmoset EAE model induced with MOG34-56
in IFA represents a high level of refinement as the det-
rimental consequences of CFA are avoided. However,
the model is insufficiently complete for serving as a
relevant preclinical model of MS as the induction of de-
myelinating antibodies by autoreactive B cells is lack-
ing. A characteristic of such pathogenic antibodies is
that they bind conformational epitopes present in the
rhMOG protein [16]. This led us to test whether EAE
can be induced by immunization of marmosets with
full-length rhMOG protein in IFA. We observed that
this is indeed the case [17].
Here, we report the immunological characterization of
the marmoset EAE model induced with rhMOG/IFA.
Antibodies binding ELISA-plate bound rhMOG and
MOG expressed in native human myelin are detectable
in the plasma of rhMOG immunized monkeys. Remark-
ably, we observed only activation of T cells against the
MOG24-36 epitope, while T cell reactivity against the
pathogenically more important epitope MOG40-48 was
absent. It is of note that the two epitopes are juxta-
positioned in an evolutionary conserved region, residues
20–50, of the extracellular MOG domain. Physiological
relevance of the strong evolutionary conservation of this
region across mammalian species (ranging from the
naked mole rat to the human) is likely, albeit poorly
understood [18].
We asked whether the absent reactivity against the
MOG34-56 peptide might be due to interaction of the
two epitopes during T cell activation or by interaction of
the anti-MOG24-36 Th1 cells with the anti-MOG40-48
CTL. These two possibilities were tested in three mar-
moset twin pairs of which one sibling was immunized
with a truncated version of rhMOG that contains both
epitopes in physically linkage, namely residues 20 to 50
in IFA, and the other sibling with the two epitopes phys-
ically unlinked, i.e. as a mixture of the immunogenic
peptides MOG14-36 and MOG34-56 in IFA. The results
show that three out of three cases immunized with the
non-linked epitopes in IFA developed clinically evident
EAE, while of the three cases immunized with the trun-
cated sequence MOG20-50 in IFA, only one developed
clinically evident EAE, albeit at a very late stage.
Methods
Animals
The marmoset monkeys selected for this study were
purchased from the purpose-bred colony of the Biome-
dical Primate Research Centre (BPRC) in Rijswijk, The
Netherlands. Individual data of the monkeys are listed in
Table 1. Before inclusion in the experiment, all marmosets
were subjected to a complete physical, hematological, and
Table 1 Overview of marmosets in experiment with their
responses to clinical EAE and presence of CNS pathology






A M08001 F 43 114 52 + −
M08093 F 36 81 72 ++ +
M08119 F 33 57 54 + −
M09047 F 28 65 56 + −
M09064 F 27 57 50 + −
M09083 F 26 111 107 + +
B 1 M09054 F 53 115 113 ++ +
M09055 F 53 120 120 + −
2 M10031 F 44 122 - + −
M10032 F 44 94 91 + −
3 M10038 F 43 122 - + −
M10039 F 43 43 40 ++ +/−
Score 2.0 ataxia or blindness, MRI magnetic resonance image, WM white
matter, GM grey matter, F female, psd post-sensitization day
aAge in months at the start of the experiment
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were under veterinary care. Monkeys in experiment were
pair-housed under conventional conditions in spacious
cages with appropriate enrichment and free access to food
and drinking water. Padded shelter was provided on the
floor. The daily diet consisted of commercial food pellets
for New World monkeys (Special Diet Services, Witham,
Essex, UK), supplemented with raisins, peanuts, marsh-
mallows, biscuits and fruit.
Ethics
In agreement with the Netherlands’ law on animal ex-
perimentation, all study protocols and experimental pro-
cedures were reviewed and approved by the Institute’s
Ethics Committee (BPRC) before the start of the experi-
ment (DEC#674 and DEC#736).
Antigens
The extracellular domain of human MOG, comprising
residues 1 to 125, was expressed as an unglycosylated re-
combinant protein in Escherichia coli and purified as
previously described (rhMOG) [5, 19]. Synthetic MOG
peptides used for immunization (residues 20–50, 14–36
and 35–56) or for in vitro assays were purchased from
Cambridge Research Biochemicals Ltd. (Cleveland, UK).
EAE induction and clinical scoring
Immunization with rhMOG (experiment A)
Six unrelated marmosets were immunized with 100 μg re-
combinant human MOG protein (rhMOG; produced in E.
coli at the BPRC), dissolved in 200 μl PBS and emulsified
in 200 μl IFA (Difco Laboratories, Detroit, MI). Monkeysthat failed to develop clinical symptoms (EAE score ≥2)
within 28 days were given a booster immunization with
freshly prepared rhMOG/IFA formulation.Immunization with MOG peptides (experiment B)
Three marmoset twins were selected for this part of the
study. One sibling of each twin was immunized twice,
on days 0 and 28, with 100 μg synthetic MOG20-50
peptide, dissolved in 200 μl PBS and emulsified in
200 μl IFA. The other sibling was immunized on days 0
and 28 with a mixture of two MOG peptides 14–36
and 34–56 (50 μg of each peptide), dissolved in 200 μl
PBS and emulsified in 200 μl IFA. On days 56 and 84,
all siblings were immunized with 100 μg MOG34-56
peptide, dissolved in 200 μl PBS and emulsified in
200 μl IFA.
All emulsions were prepared by gently stirring at
4 °C for at least 1 h, and 400 μl was injected into the
dorsal skin divided over four spots of 100 μl each,
two in the axillary, and two in the inguinal region.
Clinical signs of EAE were scored at a daily basis
using a standard scoring system [9, 11], as 0 = no
clinical signs; 0.5 = apathy, loss of appetite, altered
walking pattern without ataxia; 1 = lethargy, anorexia,
loss of tail tonus, tremor; 2 = ataxia, optic disease; 2.5 =
monoparesis or paraperesis, sensory loss; 3 = paraplegia or
hemiplegia; 4 = quadriplegia; 5 = spontaneous death due to
EAE. Overt neurological symptoms were defined as score
2 or higher. At score 3, monkeys were humanely killed for
ethical reasons.Postmortem examination
Marmoset monkeys reaching the pre-determined time
of necropsy or a maximal EAE score of 2.5 were se-
dated by intramuscular injection of alfaxan (0.2–
0.3 mg/kg) and ketamine (40–50 mg/kg) (Vétoquinol
S.A., Magny-Vernois, France). After collection of the
maximum volume venous blood (PBMC) into heparin-
ized vacutainers, monkeys were euthanized by infusion
of sodium pentobarbital (Euthesate®, Aphormo, Duiven,
The Netherlands). At necropsy, the brain and spinal
cord were removed and fixed with 4 % buffered forma-
lin. Fixed brains were analysed with magnetic reson-
ance imaging (MRI) as described for assessing the size
and spatial distribution of lesions [20, 21]. The fixed
brain and spinal cord were examined for histopatho-
logical changes [20, 21], in particular the severity of in-
flammation and demyelination. Secondary lymphoid
organs were aseptically removed for preparation of
mononuclear cells (MNC), including the spleen, axillary
(ALN), inguinal (ILN), lumbar (LLN) and cervical
(CLN) lymph node [21].
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MNC were isolated every 2 weeks from heparinized
blood or at necropsy from the spleen, ALN, ILN, LLN
and CLN, as previously described [21] and cultured with
a panel of overlapping rhMOG peptides or the complete
rhMOG protein (each 10 μg/ml). Proliferation was quan-
tified by [3H]-thymidine incorporation and expressed as
stimulation index (SI), representing the response in
antigen-stimulated versus unstimulated cultures. SI
values above 2 were considered positive as customary
for non-human primate T-cells.
Antibody detection
Antibody binding to rhMOG or to a panel of overlap-
ping MOG peptides was measured in plasma samples
using ELISA as previously described [21]. For detection
of antibody to conformationally intact MOG expressed
in myelin, marmoset CNS white matter myelin was iso-
lated by homogenization and sucrose gradient centrifu-
gation [22, 23]. Hereafter, 20 μl of 1 mg/ml myelin was
added to pre-diluted 100 μl plasma samples in a 96-well
plate, 30 min at 37 °C. After two wash steps with 180 μl
1 % BSA/PBS by centrifugation for 10 min at 4000×g,
pellet was incubated with the secondary antibody goat-
anti-monkey IgG-FITC (1:500, 100 μl/well) (Rockland,
Gilbertsville, PA), 30 min at 37 °C. IgG binding to mye-
lin particles was measured by a FACS LSRII flow cyt-
ometer using FACSDiva software (BD Biosciences).
Mean fluorescence intensity (MFI) was determined of
the FITC channel, and data was corrected for back-
ground staining (myelin particles incubated with the sec-
ondary antibody only). For blocking of anti-MOG IgG
molecules in plasma, samples were pre-incubated for 1 h
at 37 °C with a dose titration of rhMOG before it was
added to the myelin particles.
Quantitative PCR
PBMC, spleen and ALN cell suspensions were pre-
pared for total mRNA extraction using RNeasy mini-
kit (QIAGEN, Hilden, Germany), and subsequently,
cDNA was made using RevertAid First Strand cDNA
Synthesis kit (Fermentas, St. Leon-Rot, Germany) accord-
ing the manufacturer’s instructions. Quantitative PCR
(qPCR) was performed as described previously [21].
Cytokines
Supernatants of PBMC, ALN and spleen cell cultures
were collected after 48 h stimulation with rhMOG or
a panel of overlapping MOG peptides. Supernatants
were tested according to manufacturer’s instructions
with commercial ELISA kits for new world monkey
TNF-α, and new world monkey IFN-γ (both from U-
Cytech, Utrecht, The Netherlands), and human IL-
17A (eBioscience, San Diego, CA) [21].Statistical analysis
Data is presented as mean ± SEM. Statistical analysis was
performed using the Mann–Whitney U test. p values ≤0.05
were considered significant. For the immune assays,
values above the mean background ±2 SD for T-cell
proliferation (stimulation index (SI) ≥2) and antibody
production (fold increase ≥2 relative to pre-immune
serum) were considered positive.
Results
Atypical EAE induced with rhMOG in IFA
Six unrelated common marmosets were immunized with
rhMOG in IFA. Figure 1 shows that the clinical presen-
tation varied between individual monkeys, likely reflect-
ing the outbred nature of the model. Monkey M08001
displayed only a short episode of ataxia after the second
immunization, but the EAE remitted thereafter. A third
immunization with the same antigen preparation failed
to induce a relapse; this monkey was therefore sacrificed
without evident EAE symptoms. The aberrant EAE
course was reflected by the body weight measurements.
Four monkeys (M08093, M08119, M09047 and M09064)
required only two immunizations for full development
of clinically evident EAE (score 3.0; paralysis) at which
stage they were sacrificed for ethical reasons. These four
monkeys displayed the normal clinical EAE course, char-
acterized by rapid accumulation of neurological deficits.
Neurological symptoms typically started as ataxia (EAE
score 2.0) and progressed within a few days to paresis of
two hind limbs (EAE score 2.5) and paralysis of one or
both hind limbs (EAE score 3.0). The sixth monkey
(M09083) developed neurological signs after three im-
munizations and was sacrificed with EAE score 2.5 (par-
esis of two hind limbs). The disease presentation in case
M09083 differed from the remaining monkeys as its
hind limbs displayed signs of spastic paresis while the
forelimbs were weakened.
Brain lesion load assessed with MRI and histopathology
assessment
Brains collected at necropsy were briefly fixed with
buffered formalin and then examined with MRI for the
presence of lesions in the white matter using the pa-
rameters: volume, T2 relaxation time signal (T2) and
magnetization transfer ratio (MTR). White matter at-
tenuated inversions recovery (WAIR) imaging was used
for the detection of lesions in the grey matter. The 3D
reconstructions of T2-weighted MR images, visualizing
the spatial localization of lesions, show that the lesion
load is highly variable between the six analysed mon-
keys. Table 2 summarizes the MRI data of the individ-
ual monkeys.
The MRI scans revealed in all six cases the presence of
lesions in the white matter, albeit different in size and
Fig. 1 rhMOG in IFA induces clinical EAE in marmoset monkeys. Six unrelated healthy marmosets were immunized with rhMOG in IFA (post-
sensitization day 0). Monkeys not developing clinically evident EAE within 28 days were given one or two booster immunizations with the same
antigen-adjuvant emulsion (arrowheads). Clinical scores and body weights are shown for all marmosets. Clinical scores are depicted on the left
y-axis (solid line) and the percentage body weight loss compared with day 0 on the right y-axis (dotted line)
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found lesions also in the grey matter. In monkey
M08093, the highest white matter lesion volume was
detected. Figure 2 shows the presence of lesions in a se-
lected coronal slice from each marmoset brain. The T2-
weighted images (T2W) reveal lesion-like abnormalities
detected in the white matter, while the corresponding
WAIR images of the same slice show a grey matter le-
sion. Overall, the MRI-detectable brain lesion load in
this new model was remarkably low compared to the
model induced with rhMOG/CFA, despite the presence
of similar serious neurological defects in both models.
Histopathological examination (see Table 3) confirmed
the presence of moderate demyelination in the brain
white matter. In all monkeys, except the case that was
sacrificed without clinical EAE (M08001), a variable de-
gree of inflammation and demyelination was detected in
the spinal cord.
Plasma antibody levels
Plasma samples were collected at 2-week interval and at
necropsy. All samples were tested for the presence of
IgM and IgG antibodies binding to plate-bound rhMOG
or the MOG peptides 14–36, 24–46, 34–56 and 54–76
(Fig. 3). Longitudinal analysis showed that serum levels
of IgM antibodies peaked between days 14 and 28 after
immunization, while IgG levels increased progressively.
We observed relevant binding, i.e. above the cutoff level
2, of IgM antibodies in the immune sera only to
rhMOG, but to none of the MOG peptides. ElevatedIgG levels were found in all animals from day 14 after
immunization onward; IgG binding to rhMOG as well
as to peptides 14–36, 24–46 and 54–76 was detected.
The highest IgG antibody binding was measured in
M09083.
Remarkably, IgG binding to the pathogenically most
relevant MOG34-56 peptide could not be detected,
although previous studies show that immunization
with MOG peptides 34–56 in IFA elicited IgG anti-
bodies [11].
Antibody levels against native MOG
Plasma samples collected at height of the disease were
tested for IgG binding to MOG in its natural configur-
ation as it is expressed in healthy marmoset myelin.
Figure 4 shows that in all animals, a relatively high
plasma IgG reactivity with myelin particles was detected,
even in plasma samples from monkeys M08001 and
M09047, which displayed low reactivity with ELISA plate-
bound rhMOG. Data in Fig. 4c depicts that plasma IgG
binding to the myelin particles was blocked when plasma
samples were pre-incubated with a dose titration of
rhMOG. This experiment confirms that IgG binding is
really directed to MOG.
Proliferation of MNC from blood and lymphoid organs
PBMC were collected every 2 weeks and tested for
proliferation against a set of 10-mer overlapping
MOG peptides of 23 amino acids length, spanning
most of the rhMOG sequence: residues 4–26, 14–36,
Table 2 Overview of post-mortem MRI parameters of each marmoset monkey of experiment A
Animals WM NAWM WM Lesion GM NAGM GM Lesion
Volume (mm3)a M08001 61.5 61.5 0.6 107.0 107.0 –
M08093 70.3 43.6 65.1 112.8 112.7 0.6
M08119 54.1 54.1 0.6 104.5 104.5 –
M09047 48.1 48.1 0.3 99.9 99.9 –
M09064 49.1 47.5 2.8 103.0 103. –
M09083 60.8 60.8 3.8 107.1 107.1 0.2
Mean 57.3 52.6 12.2 105.7 105.7 0.4
SEM 3.5 3.0 10.6 1.8 1.8 0.2
T2 (ms) M08001 28.2 28.2 36.5 34.0 34.0 –
M08093 35.3 33.7 35.7 39.9 39.9 37.4
M08119 24.3 24.3 28.6 29.8 28.8 –
M09047 29.6 29.6 36.7 36.8 36.8 –
M09064 23.2 23.1 26.8 28.3 28.3 –
M09083 30.9 30.9 31.2 39.1 39.1 34.9
Mean 28.6 28.3 32.6 34.6 34.6 36.2
SEM 1.8 1.6 1.8 2.0 2.0 1.3
MTR (%)b M08001 40.6 40.6 33.2 27.6 27.6 –
M08093 36.5 39.9 31.4 27.4 27.4 28.8
M08119 42.0 42.0 35.5 27.8 27.8 –
M09047 42.7 72.7 33.0 28.6 28.6 –
M09064 44.0 44.2 37.8 28.7 28.7 –
M09083 42.5 42.5 34.0 28.2 28.2 27.8
Mean 41.4 42.0 34.1 28.1 28.1 28.3
SEM 1.1 0.6 0.9 0.2 0.2 0.5
aLesion volumes in GM and WM were determined in the total brain, values of WM, NAWM, GM and NAGM were only determined for a single pre-defined slice,
namely the first caudal to rostral slice that showed the complete corpus callosum connection
bMTR values are expressed as % decrease signal intensity
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Data are only shown for the peptides eliciting a detect-
able proliferative response (Fig. 5a), being peptides 14–
36 and 24–46 and for 34–56. A positive, albeit low, re-
sponse was detectable after post-immunization day
(psd) 14 against peptides 14–36 and 24–46, which de-
fines the previously identified CD4+ Th1 epitope
MOG24-36 [7]. Just like with the serum IgG, reactivity
against the peptide MOG34-56 was conspicuously ab-
sent. Figure 5b depicts the proliferation of PBMC and
MNC prepared from lymphoid organs (spleen, ALN,
ILN, LLN and CLN) at height of the disease (i.e. the
necropsy date). The figure illustrates that at this late
moment in the disease course, rhMOG reactive T cells
were not detectable in the blood, but resided in the
ALN and ILN that drain the immunization sites and in
the spleen. Proliferation activity with a SI ≥2.0 was con-
fined to rhMOG protein and to the overlapping pep-
tides 14–36 and 24–46.Antigen-induced cytokine production
For further characterization of T cell immunity in the
novel EAE model, we determined the ex vivo induction
of cytokines in cultures of MNC from the blood, spleen
and ALN stimulated with rhMOG. The culture superna-
tants were assayed for the presence of IL-17A, TNF-α
and IFN-γ (Fig. 6). Although IL-17A is the signature
cytokine of the EAE model induced with MOG34-56
peptide in IFA [11], this cytokine was undetectable in
PBMC and only at a low level in spleen and ALN. IFN-γ
production was also at a low level in the PBMC and
spleen, except for ALN cells of two monkeys (M08119
and M08093). In contrast to IL-17A and IFN-γ produc-
tion, production of the pro-inflammatory cytokine TNF-
α was found increased in all three organs, especially in
the spleen. These data suggest that immunization with
rhMOG in IFA may induce a Th1 prone cytokine profile,
which is consistent with the dominant proliferative re-
sponse of T cells against the peptides MOG14-36/
Fig. 2 MRI images. MRI scans were made of formalin fixed brains. A representative slide of T2-weighted (T2W) and white matter attenuated
inversion recovery (WAIR) images are depicted. In addition, a 3D reconstruction was made of all T2W images. The left two columns display typical slices
through the brains on which lesions in the white (red arrowheads) and grey (blue arrowheads) matter lesions can be discerned. The 3D volume shows
the total outlined volume of white (red) and grey matter (blue) lesions for each animal. Note that grey matter lesions were only observed in M08093
and M09083
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Table 3 Neuropathology quantification of the EAE model induced with rhMOG/IFA
Spinal cord Brain
Monkey Inflammation/mm2a Demyelination (%) Demyelination WM (%) Demyelination GMb
M08001 0.0 0.0 0.0 −
M08093 2.9 32.0 12.0 ±; Intracortical
M08119 0.3 1.0 0.2 −
M09047 0.1 5.4 6.5 ±; Intracortical
M09064 0.7 7.9 1.3 −
M09083 0.4 4.2 0.1 ±; Intracortical
aThe inflammatory index of the spinal cord is defined as the average number of inflamed blood vessels/spinal cord cross sections. In total, eight slices for each
animal were stained, which equals 6 cm2 in total
bDemyelination in brain GM was quantified as: + = demyelination; ± = some demyelination; − = no demyelination
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Th1 cell epitope MOG24-36 in the rhMOG/CFA
model. In none of the cultures stimulated by the MOG
peptides 14–36, 24–46, 34–56, 44–66, 54–76, 64–86,
74–96 and 84–106, we detected relevant cytokine levels
(data not shown).
mRNA transcript levels in blood and secondary lymph
nodes
Further characterization of this new EAE model was per-
formed by qPCR analysis of mRNA transcripts expressed
in MNC from ALN and spleen. For six of the markers
(IL-17A, TNF-α, CD3, IL-10, IL-7 and IFN-γ), we also
analysed mRNA expression in PBMC. Figure 7 shows
significant differences between compartments for the pa-
rameters IL-17A, TNF-α, IL-7, IL-10, CD3, CD28 and
CCR7. For the parameters IFN-γ, TGFβ, IL-2, CCR4 and
CCR6, only a trend towards different expression may be
discerned. For the markers IL-6, IL-1β, CD14 and CD19,
no differences were observed.
The higher expression level of CD3, CD28 and CCR7
in ALN than that in the spleen was not surprising, as
the ALN drain the immunization sites. This illustrates
that the immunization with rhMOG/IFA may rather in-
duce regional immune activation than the robust sys-
temic immune activation observed in the rhMOG/CFA
model. The data also show significantly higher mRNA
transcript levels for IL-17A, TNF-α, IL-10, IFN-γ and
CCR7 in ALN compared to blood, although the expres-
sion of CD3 did not significantly differ. This finding, to-
gether with the CCR mRNA expression data, hints at
broad T cell activation by the injection of rhMOG/IFA,
including Th1 (IFNγ), Th2 (CCR4), Th17 (IL-17A,
CCR6) and Tr1 (IL-10) cells. We also observed signifi-
cantly higher expression of IL-7 in the spleen than in
the blood and ALN.
A pathogenetically relevant feature detected in the
rhMOG/CFA model was IL-7 production by B cells [24].
Figure 7 shows that CD19 mRNA levels did not differ
between spleen and ALN, although production of IL-7was highest in the spleen. This may indicate that IL-7
producing activated B cells may preferentially localize in
the spleen.
Immunization with linked and unlinked MOG epitopes in
IFA
The conspicuous absence of detectable T and B cells re-
activity against the pathogenetically important MOG34-56
peptide in the rhMOG/IFA model prompted us to
test whether the absence of this specificity was due to
interaction between the two juxtapositioned epitopes,
MOG24-36 and MOG40-48. In the native MOG mol-
ecule, a N-linked glycan is attached to the MOG24-
36 epitope at the Arginine 31 residue. We showed
that the N-linked fucosylated glycan potentially pro-
hibits autoimmunity against MOG by the induction of
tolerogenic dendritic cells through binding to the C-type
lectin receptor DC-SIGN [22], but in vivo evidence
has been lacking. The observation that T cell reactiv-
ity in blood and lymphoid organs of monkeys sensi-
tized against rhMOG/IFA was directed against the
MOG24-36 epitope suggests that these T cells may
have been pre-sensitized in vivo.
The juxtaposition of the two epitopes, MOG24-36 and
MOG40-48 within the highly conserved 20–50 domain
of the MOG molecule might enable linked suppression,
as the putative Treg epitope and the Teff epitope can be
simultaneously presented on the same APC. To test this
possibility, we selected three marmoset twins, which due
to the well-established bone marrow chimerism [25] are
immunologically highly comparable. One sibling of each
twin was immunized twice (days 0 and 28) with syn-
thetic MOG20-50 peptide in IFA, in which both epi-
topes remained in physical linkage (=linked epitope
group). The other twin siblings were immunized at the
same time points with the epitopes on separate pep-
tides, i.e. MOG 14–36 and 34–56. All immunizations
were performed with IFA as adjuvant. Monkeys not de-
veloping clinical EAE were immunized twice (on days 56
and 84) with the proven encephalitogenic formulation
Fig. 3 Plasma antibody levels. Plasma samples were collected longitudinally (a) and at necropsy (b) and tested for the presence of IgM
(left column) and IgG (right column) antibodies binding ELISA-plate bound rhMOG or MOG peptides 14–36, 24–46, 34–56 and 54–76. Results
are quantitatively expressed as fold increase relative to pre-immune plasma of the same monkeys. Fold increase ≥2.0 is considered positive.
PSD post-sensitization day
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Fig. 4 Plasma IgG binding to native MOG. Necropsy plasma samples were tested for IgG binding with healthy marmoset myelin particles. a Gating
strategy: myelin particles were plotted at a logarithmic FSC and SCC scale. Middle-sized particles were selected to determine the mean
fluorescence intensity (MFI) in the FITC channel. b Marmoset myelin particles were incubated with 2000× diluted necropsy plasma samples, and IgG
binding was detected. IgG binding to myelin was expressed as mean fluorescence activity (MFI). c Plasma samples of monkey M09083 were
pre-incubated in two dilutions (1:500 and 1:5000) for 1 h at 37 °C with a dose titration of rhMOG to block anti-MOG IgG molecules. The
pre-incubated plasma samples were subsequently tested for residual IgG reactivity with marmoset myelin particles. All data were corrected
with background staining with the secondary only
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pressing anti-MOG34-56 pathogenic T cells had been
induced.
The clinical EAE scores presented in Fig. 8 show that
both siblings of twin 1 developed clinical EAE at a very
late stage and after the two immunizations with the en-
cephalitogenic formulation MOG34-56/IFA. Of twin
2, the sibling immunized with the non-linked peptides(M10039) developed severe EAE at an early stage, i.e.
prior to the challenge with MOG34-56/IFA, whereas
the sibling immunized with the linked peptides
(M10038) did not develop clinical EAE. Of twin 3,
the sibling immunized with the unlinked epitopes
(M10032) developed EAE shortly after the second
challenge with MOG34-56/IFA, whereas the sibling
immunized with the linked epitopes (M10031) did not
Fig. 5 MNC proliferation against MOG antigens. a MNC were isolated at 2-week interval from venous blood and tested for proliferation against
a panel of 23-mer overlapping MOG peptides. The positive proliferation data from individual monkeys, i.e. against MOG14-36, 24–46 and
34–56, are shown. b At necropsy, MNC were prepared from blood (PBMC), spleen, axillary (ALN), inguinal (ILN), lumbar (LLN) and cervical
(CLN) lymph nodes and were tested for their proliferation against MOG peptides and rhMOG. Data of the six monkeys are presented as
mean ± SEM. Data are expressed as stimulation index (SI) relative to unstimulated cell cultures. SI values ≥2.0 (dotted line) are considered
positive. PSD post-sensitization day
Fig. 6 Cytokine levels in culture supernatants. MNC from the blood, spleen or ALN were cultured ex vivo with rhMOG under conditions as explained
in Figure 5. After 48-h culture, supernatants were collected. Levels of IL-17A, TNF-α and IFN-γ were measured with ELISA. Data is expressed as pg/ml
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Fig. 7 Biomarker mRNA expression levels in blood and lymphoid organs. mRNA was extracted from PBMC, spleen or ALN that were collected at
necropsy. Specificity and levels of mRNA was determined with qPCR. Expression of mRNA for IL-17A, TNF-α, CD3, IL-10, IL-7 and IFN-γ was tested
in all three compartments. The other markers (IL-6, CD19, CD28, IL-1β, CCR7, Il-2, TGF-β, CCR4, CCR6 and CD14) were only tested in the spleen
and ALN. Data is expressed as relative to the household gene ABL
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oping EAE score of ≥2.0 showed a very fast disease pro-
gression from no symptoms or EAE score 0.5 (altered
walking without ataxia) to paresis or paralysis of the
hind limbs.Pathological parameters determined by MRI in the
peptide immunized marmosets
MRI data of the three twins are summarized in Table 1,
and individual data are presented in Additional file 1:
Table S1. In all monkeys, white matter lesions were
found, although the smallest white matter lesion vol-
ume was detected in M10031 and M10038. In twin 1,
the lesion load was higher in the sibling immunized
with the linked epitopes (M09054) than with the non-
linked epitopes (M09055). In contrast to twin 1, we ob-
served in twins 2 and 3 a substantially lower lesion loadin the siblings immunized with the linked epitopes
(M10031 and M10038) than with the non-linked epi-
topes (M10032 and M10039). With regard to the grey
matter lesion, these were measured in two monkeys,
namely in M09054 and M10039.
Taken together, the mean white matter lesion load is
substantially lower in the twins immunized with the
linked epitopes than those immunized with the unlinked
epitopes (55.8 ± 37.1 versus 3.9 ± 2.4). Lesion characteris-
tics, such as T2 signal intensity and MTR, did not differ
between the two groups.Antibody responses in the linked and unlinked epitope
immunized monkeys
Sera collected at periodic intervals were tested for bind-
ing to ELISA plates coated with rhMOG or MOG pep-
tides. The fold increase of IgM and IgG binding relative
Fig. 8 Clinical response to immunization with linked or unlinked epitopes in IFA. One sibling of each twin was immunized on days 0 and 28 with
peptide MOG20-50 (left column); the other sibling was immunized on the same days with a mixture of MOG14-36 and MOG34-56 (right column).
All monkeys not displaying EAE symptoms were immunized on days 56 and 84 with the encephalitogenic peptide MOG34-56. All immunizations
were with peptides emulsified in IFA. Clinical scores are depicted on the left y-axis (solid line) and the percentage body weight loss compared
with day 0 on the right y-axis (dotted line)
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shows that in monkeys immunized with the ‘linked’ epi-
topes (MOG20-50), IgM levels against MOG14-36 and
MOG34-56 were lower compared to the unlinked epi-
tope group (MOG14-36 +MOG34-56). No differences of
IgM binding to MOG24-56 were observed between the
two groups.
IgG levels against MOG34-56 in monkeys immunized
with the linked epitopes remained low for at least 80 days,
while IgG levels against MOG14-36 but not against
MOG24-46 were less reduced. Interestingly, IgG levels
against MOG34-56 were raised after the immunization
with MOG34-56/IFA. Serum levels of IgG binding
MOG14-36 and MOG34-56 were clearly higher in the
monkeys immunized with the unlinked epitopes.IgM and IgG antibody levels against MOG20-50 and
rhMOG showed exactly the same patterns as against
MOG24-56, and no positive signal was measured against
the B cell epitope MOG54-76 (data not shown). Finally,
we tested plasma samples collected at height of the dis-
ease (necropsy) for the presence of IgG reactivity with
marmoset myelin particles. Figure 4 shows that no such
reactivity was detectable.
Discussion
In the vast majority of EAE models, formulation of the
immunizing antigen with bacterial adjuvant, such as
CFA, is required for the activation of cellular and/or
humoral autoimmune mechanisms. The underlying con-
cept is that bacterial antigens relay danger signals to
Fig. 9 Plasma antibody levels in the linked or non-linked epitope group. Immune plasma samples were collected at day 0 and every 14 days
thereafter. All plasmas were tested for the presence of IgM and IgG binding to the indicated antigens coated on ELISA plates. Results of day 70
were excluded because of technical failure. Data is expressed as fold increase relative to pre-immune plasma
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pression of co-stimulatory molecules that are needed for
the full activation of tolerized autoreactive T cells [26].
While this ‘danger’ concept has been well validated for
EAE models established in immunologically immature
SPF mice [27], the question is warranted whether danger
signals are (always) needed for the activation of auto-
reactive T and B cells present in the pathogen-educated
immune system of conventionally housed primates. We
are aware of only few exceptions to the rule, namely the
inbred DA rat strain, in which EAE can be induced by
immunization with recombinant rat MOG in IFA [28]
and the outbred common marmoset in which EAE can
be induced with MOG34-56 peptide in IFA [11].
The observation that CFA can be replaced with IFA in
EAE induction protocols for non-human primates has
important implications. First, CFA is notorious for its
detrimental side effects, in particular the serious inflam-
matory skin reactions at the inoculation sites. Replace-
ment of CFA for IFA thus implies a major reduction of
discomfort for the animals. Second, activation signalsrelayed through antigen presenting cells by the myco-
bacteria in CFA not only awake anti-MOG T cells from
their tolerized state but also cause (artificial) skewing of
the T cell response towards a Th1 profile [29]. There is
increasing awareness that the Th1 bias of the EAE
model does not accurately reflect the complex immu-
nopathology of MS [30] and may explain why the ma-
jority of therapies developed in the model are directed
against Th1-driven inflammatory mechanisms. Many of
this therapeutics were ineffective during clinical tests in
relapsing-remitting MS. The anti-IL-2p40 antibody
ustekinumab and the cytokine interferon-γ are illustra-
tive examples [31, 32]. An EAE model based on IFA
lacks the polarizing effect of innate immune stimulating
adjuvant components and may therefore more closely
reflect the natural immune response of the animals
against an (injected) autoantigen.
The current study shows that six out of six marmo-
sets immunized with rhMOG in IFA developed overt
neurological signs. The data indicate that the marmo-
set’s immune repertoire contains pre-sensitized T and
Fig. 10 Linked suppression paradigm for the absent activation of
MOG34-56-reactive T cells. We postulate that the marmoset’s immune
repertoire contains pre-sensitized autoreactive T cells against two
dominant MOG epitopes, i.e. the CD4 cells/Th1 epitope 24–36
(blue triangle) and the CTL epitope 40–48 (red circle), which are
juxta-positioned in an evolutionary conserved region in the extracellular
domain, residues 20–50. In monkeys immunized with the MOG20-50
peptide, both epitopes are processed and presented simultaneously on
the APC surface. Conceptually, this implies that reactivation of CTL cells
by the 40–48 epitope (red repertoire) may be blunted by Tr1 cells
re-activated at the same APC by the MOG24-36 epitope
(blue repertoire)
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topes derived from rhMOG by antigen presenting
cells, which have not been exposed to danger signals.
Remarkably, we detected T cell reactivity with only
two peptides (MOG14-36 and MOG24-46; shared epitope
24–36), while previous studies identified a second and
pathogenically highly important epitope within peptide
MOG34-56 (epitope 40–48) [11]. A previous study in the
EAE model induced with rhMOG in CFA identified
MOG24-36 as the epitope of pro-inflammatory Th1 cells,
presented by the monomorphic MHC class II/Caja-
DRB*W1201 allele [7]. We propose that in the rhMOG/
IFA model that lacks danger signals, the autoreactive
CD4+ T cells responding to MOG24-36 may differen-
tiate into Tr1 direction.
The absence of reactivity against the MOG34-56 peptide
in the current study is confusing as the 100 % EAE re-
sponse to immunization with the mixture of MOG14-36
and MOG34-56 peptide in IFA (experiment B, Fig. 8) con-
firms the previous finding [11] that T cells capable to re-
spond to the MOG34-56 peptide are present in the
marmoset’s immune repertoire. The observation that EAE
development is impaired in the fraternal siblings, which
were immunized with the MOG20-50 peptide in IFA, may
indicate that T cell activation against MOG34-56 is
blunted when the core epitopes MOG40-48 and MOG24-
36 are co-expressed in the same peptide. Note that also
the IgG response against MOG34-56 was impaired in
monkeys immunized with MOG20-50 in IFA (Fig. 9).
It is tempting to speculate on a possible explanation
for this unexpected observation, although conclusive ex-
perimental evidence is lacking. The MOG24-36 epitope
is special as the arginine residue at position 31 is the
only N-glycosylation site present in MOG. We reported
previously that the N-linked glycan has an important
physiological function as through binding with the C-
type lectin receptor DC-SIGN dendritic cells (by DC)
are retained in an immature anti-inflammatory/tolero-
genic state [22]. It has been shown that antigens cap-
tured by DC-SIGN are internalized and processed by the
tolerogenic DC and that peptides are presented to T cells,
which develop towards anti-inflammatory or regulatory
functions [33]. This led us to postulate that (part of) the
MOG specific T cells present in the normal repertoire
may have a suppressive/regulatory function, serving the
maintenance of homeostasis [34, 35]. Conceptually, it can
thus be envisaged that in the monkeys immunized with
the MOG20-50 peptide, the MOG24-36 and MOG40-48
epitopes are processed and presented simultaneously by
the same APC (see Fig. 10). In this setting, activation of
the pathogenic T cell by MOG40-48 would be blunted by
the simultaneous activation of ‘putative’ regulatory cells
by MOG24-36, a situation reminiscent of the linked sup-
pression paradigm [36].Conclusion
In conclusion, the novel IFA-based MOG-induced EAE
models in the marmoset reveal presence of pre-
sensitized autoreactive T cells in the normal repertoire.
The immunodominant epitopes are the same as those
identified in the corresponding CFA-based models,
namely residues 24–36 and 40–48. Paradoxically, we
observed in the rhMOG/IFA model that activation of
CD8+ CTL against MOG40-48 could not be detected.
Based on previous work, we propose that (part of ) the
anti-MOG24-36 CD4+ T cells have regulatory/suppres-
sive function. These may prohibit activation of highly
pathogenic CTL via a mechanism reminiscent to linked
suppression. The reason why the rhMOG/IFA immu-
nized marmosets nevertheless develop EAE is unclear.
The possibility that T cells against subdominant epi-
topes, such as 4–26 or 94–106 [7], in synergy with anti-
MOG antibodies may elicit inflammatory demyelination
of the CNS is subject of investigation.
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